Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...
Zacks.com on MSN19h
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to NoteThe latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...
The artificial intelligence (AI) boom has taken the stock market by storm. Wall Street is currently fixated on AI agents, which differ slightly from traditional AI copilots. Alphabet (NASDAQ: GOOGL) ...
TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 20 years ago, it would be worth $39,441.77 today based on ...
Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...
The stock's fall snapped a three-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback